


# Introducing Ethiq XR® –

The first and only FDA reviewed and accepted buprenorphine that provides 72 hours control of post-procedural pain in mice, rats, and ferrets, and non-human primates.

For more days of comfort at home



 **Ethiq XR®** 

(buprenorphine extended-release injectable suspension)  
1.3 mg/mL

## Important Safety Information For Rats, Mice, Ferrets, and Non-Human Primates:

Only administer Ethiq XR® by subcutaneous injection. Ethiq XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.

Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiq XR have been administered concomitantly in mice.

Do not house rats on wood chip-type bedding after administration of Ethiq XR. **Pica involving wood chip type bedding can be lethal.**

Ethiq XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiq XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiq XR.

The safety of Ethiq XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.

## For Humans:

Not for use in humans. Keep out of reach of children and pets.

**Ethiq XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.**

Ethiq XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.

Ethiq XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiq XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.

*For more information, consult the Prescribing Information including the Boxed Warning.*

Ethiqa XR®: the only FDA-indexed pharmaceutical-grade extended-release buprenorphine for control of post-procedural pain in mice, rats, ferrets, and non-human primates

Now available for your practice!



With just 1 subcutaneous injection, Ethiqa XR...



Provides long-lasting relief: 72 hours of control of post-procedural pain<sup>1,2,3</sup>



Acts fast: Achieves therapeutic blood levels within 30 minutes in ferrets and mice, and 6 hours in rats<sup>1,2,3</sup>



Extended-release analgesics, like Ethiqa XR, offer multiple advantages, including:

- ✓ Reduced animal handling
- ✓ Improved compliance
- ✓ Reduced injection frequency
- ✓ Limiting the possibility of breakthrough pain

In a comparative analgesic study<sup>1</sup> following routine ovariohysterectomy, ferrets receiving Ethiqa XR...

- had significantly lower respiratory rates and posture scores versus short-acting BUP HCl
- were less likely to react to surgical incision palpation overall

Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans. For more information, consult the Prescribing Information including the Boxed Warning.

1. Plunkard J, Jimenez I, Crane M, Villano J. Pharmacokinetics and efficacy of extended-release buprenorphine for post-operative pain management in the domestic ferret (*Mustela putorius furo*). Submitted for publication; 2024.  
2. Journal of Veterinary Medicine, Vol 2017, 4/2019.  
3. Data on file, Fidelis Animal Health.

Ethiqa XR®—quality and confidence for your rat and ferret pain management protocols

	Ethiqa XR	Compounded Drugs
FDA-Indexed	✓	✗
Pharmaceutical Grade	✓	✗
cCMP	✓	✗
Not compounded	✓	✗

- The safety and efficacy of Ethiqa XR have been reviewed and accepted by the FDA, an established process called Drug Indexing.<sup>3</sup>
- Fidelis Animal Health monitors adverse event reports and updates its labeling to provide users of the drug with important prescribing information.
- Ethiqa XR contains no endotoxins or polymers, which are known to cause injection site reactions.<sup>3</sup>



Scan for more info at [EthiqaXR.com](https://EthiqaXR.com)



Ethiqa XR is conveniently and readily available from your favorite distributor:

Distributor	Phone Number	Product Number
MWI Animal Health	800-824-3703	86084-100-30
Covetrus	855-724-3461	072117
Midwest Vet	800-MIDWEST	267.10000.3
Patterson	800-225-7911	07-894-7617
Hanna	302-571-8761	86084-0100-30

**Important Safety Information For Rats, Mice, Ferrets, and Non-Human Primates:**

Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise. Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice. Do not house rats on wood chip-type bedding after administration of Ethiqa XR. **Pica involving wood chip type bedding can be lethal.** Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR. The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.

**For Humans:**

Not for use in humans. Keep out of reach of children and pets. **Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.** Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law. Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.

For more information, consult the Prescribing Information including the Boxed Warning.

An extended-release formulation using the Fidelipid LAI™ technology from

**Fidelis** ANIMAL HEALTH  
685 US Highway One, Suite 265, North Brunswick, NJ 08902  
833-ETHIAXR (833-384-4729)  
Manufactured for Fidelis Animal Health, Inc.

**Ethiqa XR®** (buprenorphine extended-release injectable suspension) 1.3 mg/mL

Ethiqa XR® is a registered trademark of Fidelis Animal Health, Inc. © 2024 Fidelis Animal Health, Inc. All rights reserved. SA.EthiqaXR.098.01.24

